Health & Fitness
Mon, February 23, 2009Sun, February 22, 2009Fri, February 20, 2009Thu, February 19, 2009Wed, February 18, 2009Tue, February 17, 2009Mon, February 16, 2009Fri, February 13, 2009Thu, February 12, 2009Wed, February 11, 2009Tue, February 10, 2009Mon, February 9, 2009Sun, February 8, 2009Fri, February 6, 2009Thu, February 5, 2009Hythiam Announces Presentation at the Roth 21st Annual OC Growth Stock Conference
Published in Health and Fitness on Thursday, February 12th 2009 at 5:30 GMT, Last Modified on 2009-02-12 05:31:44 by Market Wire
LOS ANGELES--([ BUSINESS WIRE ])--Hythiam, Inc. (NASDAQ:HYTM) announced today that Terren Peizer, Chairman and Chief Executive Officer of Hythiam, will be presenting at the Roth Capital Partners 21st Annual OC Conference on Wednesday, February 18, 2009 at 5:00 p.m. PST. The event will be held February 16-18, 2009 at the Ritz-Carlton in Dana Point, California.
To access the Roth Capital Partners conference webcast, please visit [ http://www.roth.com/main/Page.aspx?PageID=7214 ]. Hythiam's webcast will also be available on its website at [ www.hythiam.com ], where it will be archived for 14 days following the conference.
About Hythiam®
Hythiam, Inc. provides through its CatasysTM offering, behavioral health management services to health plans, employers and unions through a network of licensed and company managed healthcare providers. Catasys offers integrated substance dependence solutions built around the patented PROMETA® Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers and company managed treatment centers. Hythiam also researches, develops, licenses and commercializes innovative and proprietary physiological, nutritional, and behavioral treatment programs. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA Treatment Program. For further information, please visit [ www.hythiam.com ].
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and lack of statistically significant formal research studies, the risk that treatment protocols might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry; and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at [ http://www.sec.gov ].
